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Supplementary Fig. 1 Low BCL-XL mRNA expression in melanoma biases the pro-survival mRNA pool towards MCL1. a MCL1:BCL-XL mRNA 
expression ratio obtained from the Cancer Cell Line Encyclopedia RNA-sequencing data for the indicated tumour lineages. CRC, colorectal cancer; 
NSCLC, non-small cell lung cancer; CNS, central nervous system; SCLC, small cell lung cancer. b-d RNA-sequencing mRNA expression data 
obtained from the Cancer Cell Line Encyclopedia for BCL2 (b) BCL-w (BCL2L2) (c) and A1 (BCL2A1) (d) in CRC, melanoma, NSCLC and pancreatic 
tumour cells measured in reads per kilobase million (RPKM). a-d Data are presented on a log2 scale as either antilog (a, b, c) or log2 (d) values, and 











































































































































































































































































































Supplementary Fig. 2 Low BCL-XL protein expression in melanoma biases the pro-survival protein pool towards MCL1. a, b Seven colorectal 
cancer (CRC; left) and seven melanoma (right) cell lines were cultured for 24 hours before lysis and western blotting with the indicated antibodies. 
Quantification of BCL2 (a) and BCL-w (b) levels relative to A375 cells was performed by quantitative western blotting with fluorescently labelled 
secondary antibodies. Results are mean ± SD from three independent experiments. c, d 32.5-600 fmol of recombinant human MCL1 (c) or BCL-
XL (d) was subjected to SDS-PAGE and quantitative western blotting with fluorescently labelled secondary antibodies. Representative standard 
curves used for absolute quantification of MCL1 and BCL-XL are shown. e-h MCL1 and BCL-XL expression were quantified absolutely in the 
CRC (e), melanoma (f), non-small cell lung cancer (NSCLC; g) and pancreatic (h) tumour cell lines indicated using recombinant protein standards 
and quantitative western blotting with fluorescently labelled secondary antibodies. Results are mean ± SD from three independent experiments 
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplementary Fig. 3 MEK1/2 inhibitors synergise with the MCL1 antagonist AZD5991 or BCL2/BCL-w/BCL-XL antagonist AZD4320 to kill 
melanoma tumour cells. Melanoma cell lines were treated with the indicated concentrations of trametinib or selumetinib in combination with 
AZD5991 or AZD4320 for 5 days. The number of viable cells was determined at the point of treatment (day 0) and at the end of the experiment using 
Sytox Green. 100% represents the number of viable cells in the control wells at day 5, 0% is equivalent to the number of viable cells on day 0 and 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplementary Fig. 4 MEK1/2 inhibitors synergise with the MCL1 antagonist AZD5991 or BCL2/BCL-w/BCL-XL antagonist AZD4320 to kill 
melanoma tumour cells. Melanoma cell lines were treated with the indicated concentrations of trametinib or selumetinib in combination with 
AZD5991 or AZD4320 for 5 days. The number of viable cells was determined at the point of treatment (day 0) and at the end of the experiment using 
Sytox Green. 100% represents the number of viable cells in the control wells at day 5, 0% is equivalent to the number of viable cells on day 0 and 










































































































































































































































































































































































































































































































































































































































































Supplementary Fig. 5 MEK1/2 inhibitors synergise with the MCL1 antagonist AZD5991 or BCL2/BCL-w/BCL-XL antagonist AZD4320 to kill 
melanoma and colorectal cancer (CRC) tumour cells. Melanoma and CRC cell lines were treated with the indicated concentrations of trametinib or 
selumetinib in combination with AZD5991 or AZD4320 for 5 days. The number of viable cells was determined at the point of treatment (day 0) and 
at the end of the experiment using Sytox Green. 100% represents the number of viable cells in the control wells at day 5, 0% is equivalent to the 





































































































































































































































































































































































































































































Supplementary Fig. 6 The BRAFi vemurafenib or the ERKi SCH772984 synergises with the MCL1 antagonist AZD5991 or BCL2/BCL-w/BCL-XL 
antagonist AZD4320 to kill melanoma tumour cells. Melanoma cell lines were treated with the indicated concentrations of trametinib or selumetinib 
in combination with AZD5991 or AZD4320 for 5 days. The number of viable cells was determined at the point of treatment (day 0) and at the end of 
the experiment using Sytox Green. 100% represents the number of viable cells in the control wells at day 5, 0% is equivalent to the number of viable 



























































































































































































Supplementary Fig. 7 ERK1/2 pathway inhibitors combine with the MCL1 antagonist AZD5991 to selectively kill melanoma tumour cells. a A375 
cells were treated with the indicated concentrations of selumetinib (Sel) with or without 1 μM AZD5991 for 48 hours. b A375 cells were treated with 
the indicated concentrations of AZD5991 with or without 1 μM selumetinib (Sel) for 48 hours. c SK-MEL-30 cells were treated with the indicated 
concentrations of selumetinib (Sel) with or without 1 μM AZD5991 for 48 hours. d SK-MEL-30 cells were treated with the indicated concentrations of 
AZD5991 with or without 1 μM selumetinib (Sel) for 48 hours. a-d Cell cycle profile was determined by propidium iodide staining and flow cytometry. 
e WM266-4 cells were treated with the indicated concentrations of vemurafenib (Vem) with or without 1 μM AZD5991 for 48 hours. f SK-MEL-30 cells 
were treated with the indicated concentrations of selumetinib (Sel) with or without 1 μM AZD5991 for 48 hours. g, h SK-MEL-30 cells were treated 
with the indicated concentrations of AZD5991 (g) or AZD4320 (h) with or without 1 μM selumetinib (Sel) for 48 hours. i, j A375 (i) and SK-MEL-30 
(j) cells were treated with the indicated concentrations of navitoclax (ABT-263) with or without 1 μM selumetinib (Sel) for 48 hours. k, l A375 (k) and 
SK-MEL-30 (l) cells were treated with the indicated concentrations of venetoclax with or without 1 μM selumetinib (Sel) for 48 hours. e-l Apoptosis 
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Supplementary Fig. 8 ERK1/2 pathway inhibitors combine with the MCL1 antagonist AZD5991 to inhibit clonogenic survival and tumour growth 
in xenografts. a A375 cells seeded at low density were treated with DMSO control (C), 2 μM vemurafenib (Vem), 1 μM navitoclax (ABT-263) or the 
combination as indicated for 72 hours, after which time cells were washed and grown for a further four days. Colonies were visualised by crystal 
violet staining and counted, and cell growth assessed following solubilisation. Results are mean ± SD of three independent experiments. b Results as 
described in Fig. 3d but with tumour growth shown as geometric mean ± SEM. c Results as described in Fig. 3e showing the individual data points 
overlaid. Error bars are mean ± SEM. d As in Fig. 3d, female nude athymic mice were implanted subcutaneously with A375 cells and randomised 
21 days later for dosing with either vehicle only (Control, n = 5), 25 mg kg−1 selumetinib (Sel, n = 7) twice daily with an 8 hour interval, 60 mg kg−1 
AZD5991 (n = 7) intravenously once weekly, or the combination of 25 mg kg−1 selumetinib and 60 mg kg−1 AZD5991 (Sel + AZD5991, n = 8) for a 























































































































































Supplementary Fig. 9 Combinations of ERK1/2 pathway inhibitors and the MCL1 antagonist AZD5991 regress or inhibit tumour growth and are 
tolerated in vivo. a, b Results as described in Fig. 4g, i but with tumour growth shown as geometric mean ± SEM. c-f Results as described in Fig. 
4h, j, l, n showing the individual data points overlaid. Error bars are mean ± SEM. g-j As in Fig. 4g-n, NOD SCID mice implanted subcutaneously 
with MEDI-MEL-02 (g, h) or MEDI-MEL-10 (i, j) tumour pieces and dosed (n = 9 or 10 per group) as indicated with vehicle only (Control), 20 mg kg−1 
vemurafenib (Vem) twice daily with an 8 hour interval, 1 mg kg−1 trametinib (Tra) daily, and/or 60 mg kg−1 AZD5991 three times per week. Mice were 
dosed on these schedules throughout the duration of the experiment, except in (j) for which dosing ceased after day 32. Mouse body mass was 



















































































































































































































































































































































































































































Supplementary Fig. 10 ERK1/2 pathway inhibitors prime tumour cells for rapid induction of BAK/BAX-dependent apoptosis upon MCL1 antagonism. 
a A375 cells were treated with DMSO vehicle only (Control) or 1 μM selumetinib (Sel) for 24 hours as indicated. 1 μM AZD5991 was then added for 
the indicated times and apoptosis assessed by Annexin V staining and flow cytometry. b HCT116, HCT116 BAK KO, HCT116 BAX KO and HCT116 
BAK BAX DKO isogenic cell lines were treated with DMSO control (C), 2 μM selumetinib (Sel), 1 μM AZD5991 or 2 μM selumetinib plus 1 μM AZD5991 
(Sel + AZD5991) with or without 20 μM Q-VD-OPh (Sel + AZD5991 + QVD) for 48 hours. Annexin V or DAPI positive cells were assessed by flow 

































































































































































































































Supplementary Fig. 11 Apoptosis induced by combined ERK1/2 pathway and MCL1 inhibition causes BIM and BMF redistribution to other pro-
survival proteins. a A375 cells were treated with the indicated concentrations of selumetinib (Sel) with or without 1 μM AZD5991 for 24 hours. 
Whole-cell lysates were subjected to SDS-PAGE and western blotted with the indicated antibodies. b A375 cells were treated with the indicated 
concentrations of AZD5991 with or without 1 μM selumetinib (Sel) for 24 hours. Whole-cell lysates were subjected to SDS-PAGE and western 
blotted with the indicated antibodies. c A375 cells were treated with DMSO vehicle only (C and 5991) or 1 μM selumetinib (Sel and Sel + 5991) for 
24 hours followed by DMSO only (C and Sel) or 1 μM AZD5991 (5991 and Sel + 5991) for a further four hours. Lysates (input) were subjected to 
immunoprecipitation with antibodies to BCL-XL or MCL1. Input lysates, immunoprecipitates (IP) and supernatant unbound fractions (UNB) were then 
western blotted with the indicated antibodies. d SK-MEL-30 cells were treated with DMSO vehicle only (C and 5991) or 1 μM selumetinib (Sel and 
Sel + 5991) for 24 hours followed by DMSO only (C and Sel) or 1 μM AZD5991 (5991 and Sel + 5991) for a further four hours. Lysates (input) were 
subjected to immunoprecipitation with antibodies to BCL-XL or MCL1. Input lysates, immunoprecipitates (IP) and supernatant unbound fractions 







































































































































































































Supplementary Fig. 12 Combined ERK1/2 and MCL1 inhibition can overcome acquired resistance to BRAFi and/or MEKi. a A375 and PLX4720-
resistant A375 (A375 PLX-R) cells were washed and treated with DMSO control only (C), 0.3 μM SCH772984 (SCH), 1 μM AZD5991 (5991) or the 
combination (SCH + 5991) for 48 hours, either in the presence (PLX) or absence of 0.66 μM PLX4720, the normal growth medium of A375 PLX-R. 
b A375 and selumetinib-resistant A375 (A375 Sel-R) cells were washed and treated with DMSO control only (C), 0.3 μM SCH772984 (SCH), 1 μM 
AZD5991 (5991) or the combination (SCH + 5991) for 48 hours, either in the presence (Sel) or absence of 0.5 μM selumetinib, the normal growth 
medium of A375 Sel-R. c A375 and selumetinib/PLX4720-resistant A375 (A375 PLX/Sel-R1) cells were washed and treated with 0.3 μM SCH772984 
(SCH), 1 μM AZD5991 (5991) or the combination (SCH + 5991) for 48 hours, either in the presence (PLX + Sel) or absence of 0.33 μM PLX4720 and 
0.25 μM selumetinib, the normal growth medium of A375 PLX/Sel-R1. a-c Cell cycle profile was determined by propidium iodide staining and flow 
cytometry. Results show mean ± SD of four independent experiments. d-g DNA extracted from A375, A375 PLX/Sel-R1 (d, e) and A375 PLX/Sel-R2 































































































































































































































































































































































































































































































































Supplementary Fig. 13 A375 cells acquire resistance to PLX4720 and/or selumetinib by reinstating ERK1/2 signalling. a-d DNA extracted from A375 
(a-d) and PLX4720-resistant A375 (A375 PLX-R) cells (a), selumetinib-resistant A375 (A375 Sel-R) cells (b) and selumetinib/PLX4720-resistant 
A375 (A375 PLX/Sel-R1 and A375 PLX/Sel-R2) cells (c, d) was subjected to next-generation sequencing and copy number analysis. e A375, A375 
Sel-R, A375 PLX-R, A375 PLX/Sel-R1 (5×IC50) and A375 PLX/Sel-R2 (10×IC50) cells were washed and treated with DMSO only control (C), 0.5 μM 
selumetinib (Sel), 0.66 μM PLX4720 (PLX), 0.25 μM selumetinib plus 0.33 μM PLX4720 (PLX + Sel (5×)) or 0.5 μM selumetinib plus 0.66 μM PLX4720 
(PLX + Sel (10×)) as indicated. Whole-cell lysates were western blotted with the indicated antibodies. f A375, A375 Sel-R cells, A375 PLX-R cells and 
A375 PLX/Sel-R2 cells were washed and treated with DMSO only control (C), 0.5 μM selumetinib (Sel), 0.66 μM PLX4720 (PLX) or 0.5 μM selumetinib 
plus 0.66 μM PLX4720 (PLX + Sel), as indicated, either with or without 0.3 μM SCH772984. Whole-cell lysates were western blotted with the indicated 
antibodies. g As in Figure 8b female athymic nude mice were injected subcutaneously with A375 PLX/Sel-R2 cells and dosed with vehicle only 
(Control, n = 10), 50 mg kg−1 AZ13776197 (AZ6197, n = 10) orally once daily, 60 mg kg−1 AZD5991 (AZD5991, n = 10) once weekly intravenously, or 























































































































Supplementary Fig. 14 Melanoma cells acquire resistance to combined ERK1/2 pathway and MCL1 inhibition by reinstating ERK1/2 signalling. 
a, b Two independently derived sets (R2 and R3) of A375, vemurafenib-resistant A375 (Vem-R) cells, AZD5991-resistant A375 (5991-R) cells and 
vemurafenib/AZD5991-resistant A375 (Vem/5991-R) cells were washed and treated with DMSO only control (C), 2 μM vemurafenib (Vem) and/or 1 
μM AZD5991 (5991) with or without 1 μM SCH772984 (SCH) as indicated for 48 hours. c SK-MEL-30, selumetinib-resistant SK-MEL-30 (Sel-R) cells, 
AZD5991-resistant SK-MEL-30 (5991-R) cells and selumetinib/AZD5991-resistant SK-MEL-30 (Sel/5991-R) cells were washed and treated with 
DMSO only control (C), 1 μM selumetinib (Sel) and/or 1 μM AZD5991 (5991) with or without 1 μM SCH772984 (SCH) as indicated for 48 hours. a-c 
Cell cycle profile was determined by propidium iodide staining and flow cytometry. Results are mean ± SD of three or four independent experiments. 
d SK-MEL-30, selumetinib-resistant SK-MEL-30 (Sel-R) cells, AZD5991-resistant SK-MEL-30 (5991-R) cells and selumetinib/AZD5991-resistant SK-
MEL-30 (Sel/5991-R) cells were washed and treated with DMSO only control (C), 1 μM selumetinib (Sel) and/or 1 μM AZD5991 (5991) as indicated 
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Supplementary Table 1. ERK1/2 pathway component mutations in the cell lines used for high-




BRAF EGFR KRAS HRAS MAP2K1 NF1 NRAS 
Colorectal CO115 V600E N/A WT N/A N/A N/A N/A 
COLO205 V600E WT WT WT WT WT WT 
DLD1 WT WT G13D WT WT A2617V WT 
HCA7 WT WT WT WT WT P228L WT 






WT WT WT WT WT WT 
LoVo WT WT G13D WT WT R1695Q WT 
NCI-H747 WT WT G13D WT WT WT WT 




SW480 WT WT G12V WT WT WT WT 
SW620 WT WT G12V WT WT WT WT 
SW837 WT WT G12C WT WT WT WT 
Melanoma A2058 V600E WT WT WT P124S WT WT 
A375 V600E WT WT WT WT WT WT 
CHL-1 WT V1011M WT WT WT WT WT 
HMCB WT WT WT WT WT Q535H WT‡ 
MEL-JUSO WT WT WT G13D WT L1779P Q61L 
MeWo WT WT WT WT WT Q1336* WT 
SK-MEL-2 WT WT WT WT WT N1250fs*3 Q61R 
SK-MEL-5 V600E WT WT WT WT WT WT 
SK-MEL-28 V600E P753S WT WT WT WT WT 
SK-MEL-30 E275K; 
D287H 
WT WT WT WT WT Q61K 
WM266-4 V600E† WT WT WT WT WT WT 
WM852 WT N/A N/A N/A N/A N/A Q61R 
* Introduces stop codon. 
† Variously reported as V600D or V600E. 
‡
 HMCB reported to be NRASQ61K mutant in Davies et al.1. 
Data curated from Catalogue of Somatic Mutations in Cancer (COSMIC; https://cancer.sanger.ac.uk/cosmic), except SW480, 
HMCB, MeWo and WM266-4 which show data from the Cancer Cell Line Encyclopedia (CCLE; 
https://portals.broadinstitute.org/ccle); fs, frameshift; N/A, not available; WT, wild type. Predicted zygosity: heterozygous 
(blue); homozygous (red); unknown (black). 
 
  
Supplementary Table 2. Loewe synergy scores by cell line. 
 
Cell line Mutations 
Loewe synergy score 
Tra + 5991 Tra + 4320 Sel + 5991 Sel + 4320 
Colorectal CO115 BRAF 2.35 0.77 1.50 0.11 
COLO205 BRAF 31.85 57.41 25.17 33.46 
DLD1 KRAS, NF1 2.58 16.30 1.51 5.54 
HCA7 NF1 37.10 26.58 21.96 20.11 
HCT116 KRAS, NF1 7.31 12.21 1.46 4.66 
HT29 BRAF 7.20 25.24 6.98 14.85 
LoVo KRAS, NF1 4.51 5.36 2.46 2.42 
NCI-H747 KRAS 1.72 14.58 0.45 9.35 
SW48 EGFR, MEK1 16.19 19.96 11.97 9.18 
SW480 KRAS 9.16 19.56 8.32 9.76 
SW620 KRAS 9.56 12.34 5.78 9.74 
SW837 KRAS 7.30 17.67 2.52 13.37 
Melanoma A2058 BRAF, MEK1 30.56 16.45 10.27 5.78 
A375 BRAF 28.63 22.12 25.42 12.34 
CHL-1 EGFR 16.10 10.48 16.55 7.14 
HMCB NF1 7.42 11.26 3.68 5.70 
MEL-JUSO HRAS, NRAS, NF1 22.28 29.23 15.28 15.48 
MeWo NF1 14.18 18.56 11.06 5.21 
SK-MEL-2 NRAS, NF1 21.24 20.16 16.46 5.08 
SK-MEL-5 BRAF 26.53 18.31 19.72 12.17 
SK-MEL-28 BRAF, EGFR 33.86 37.10 20.24 29.79 
SK-MEL-30 NRAS, BRAF 27.65 17.32 22.78 9.97 
WM266-4 BRAF 37.67 37.97 34.36 37.08 
WM852 NRAS 20.21 20.12 9.39 7.91 
 
Supplementary Table 3. Reagents and resources used in this study. 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
α-tubulin WB 1:500 Sigma-Aldrich Cat#T9026 
Anti-mouse Alexa Fluor 488 antibody FC 1:200 Thermo Fisher Scientific Cat#A-11001 
Anti-mouse DyLight 800 4X PEG conjugate WB 1:15000 Cell Signaling Technology Cat#5257 
Anti-rabbit DyLight 800 4X PEG conjugate WB 1:15000 Cell Signaling Technology Cat#5151 
ARAF; rabbit polyclonal WB 1:1000 Cell Signaling Technology Cat#4432 
β-actin; mouse monoclonal (clone AC-15) WB 1:2000 Sigma-Aldrich Cat#A5441 
BAD; rabbit monoclonal (D24A9) WB 1:1000 Cell Signaling Technology Cat#9239 
BAK; rabbit polyclonal WB 1:500 Santa Cruz Biotechnology Cat#sc-832 
BAX; rabbit polyclonal WB 1:500 Santa Cruz Biotechnology Cat#sc-493 
BAX; mouse monoclonal (clone 6A7) FC 1:50 
WB 1:500 
BD Biosciences Cat#556467 
BCL2; mouse monoclonal (clone C-2) WB 1:500 Santa Cruz Biotechnology Cat#sc-7382 
BCL-w; rabbit monoclonal (clone 31H4) WB 1:1000 Cell Signaling Technology Cat#2724 
BCL-XL; rabbit monoclonal (clone 54H6) WB 1:1000 Cell Signaling Technology Cat#2764 
BCL-XL; rabbit polyclonal WB 1:1000 Cell Signaling Technology Cat#2762 
BID; rabbit polyclonal WB 1:1000 Cell Signaling Technology Cat#2002 
BIM; rabbit monoclonal (clone C34C5) WB 1:1000 Cell Signaling Technology Cat#2933 
BIM; rabbit polyclonal WB 1:1000 Merck Millipore Cat#AB17003 
BMF; rat monoclonal (clone 9G10) WB 1:500 Enzo Life Sciences Cat#ALX-804-343 
BRAF; rabbit polyclonal WB 1:500 Santa Cruz Biotechnology Cat#sc-166 
CRAF; rabbit polyclonal WB 1:500 Santa Cruz Biotechnology Cat#sc-227 
ERK1/2; rabbit monoclonal (clone 137F5) WB 1:1000 Cell Signaling Technology Cat#4695 
GAPDH; rabbit monoclonal (clone EPR16891) WB 1:2000 Abcam Cat#ab181602 
Goat anti-mouse IgG (H + L)-HRP conjugate  WB 1:3000 Bio-Rad Cat#1706516 
Goat anti-rabbit IgG (H + L)-HRP conjugate  WB 1:3000 Bio-Rad Cat#1706515 
KRAS; rabbit polyclonal WB 1:500 Proteintech Cat#12063-1-AP 
MCL1; rabbit monoclonal (clone D2W9E) WB 1:1000 Cell Signaling Technology Cat#94296 
MCL1; rabbit polyclonal WB 1:500 Santa Cruz Biotechnology Cat#sc-819 
MEK1/2; rabbit polyclonal WB 1:1000 Cell Signaling Technology Cat#9122 
NOXA; mouse monoclonal (clone 114C307) WB 1:200 Merck Millipore Cat#OP180  
NRAS; rabbit polyclonal WB 1:500 Santa Cruz Biotechnology Cat#sc-519 
PARP; rabbit polyclonal WB 1:1000 Cell Signaling Technology Cat#9542 
RSK; rabbit monoclonal (clone 32D7) WB 1:1000 Cell Signaling Technology Cat#9355 
Phospho-ERK1/2 T185 Y187/T202 Y204; rabbit 
polyclonal 
WB 1:1000 Cell Signaling Technology Cat#9101 
Phospho-MEK1/2 S218 S222/S222 S226; rabbit 
polyclonal 
WB 1:1000 Cell Signaling Technology Cat#9121 
Phospho-RSK TS359; rabbit monoclonal (D1E9) WB 1:1000 Cell Signaling Technology Cat#8753 
PUMA; rabbit monoclonal (D30C10) WB 1:1000 Cell Signaling Technology Cat#12450 
Biological Samples 
Colorectal and melanoma patient-derived xenograft tissue AstraZeneca PDX library N/A 
Chemicals, peptides, and recombinant proteins 
Recombinant human BCL-XL R&D Systems Cat#894-BX-050 
Recombinant human MCL1 Cloud-Clone Corp Cat#RPC615Hu01 
A-1155463 BCL-XL inhibitor Adooq Bioscience Cat#A16112 
CAS: 1235034-55-5 
AZ6197 ERK1/2 inhibitor Provided by AstraZeneca N/A 
AZD4320 BCL-w/BCL-XL/BCL2 inhibitor Provided by AstraZeneca N/A 
AZD5991 MCL1 inhibitor Provided by AstraZeneca N/A 
PLX4720 RAF inhibitor Selleck Chemicals Cat#S1152; 
CAS: 918505-84-7 
Q-VD-OPh pan-caspase inhibitor Adooq Bioscience Cat#A14915; CAS: 
1135695-98-5 
SCH772984 ERK1/2 inhibitor Selleck Chemicals Cat#S7101; CAS: 
942183-80-4 
Selumetinib (AZD6244) MEK1/2 inhibitor Provided by AstraZeneca CAS: 606143-52-6 
Trametinib MEK1/2 inhibitor Selleck Chemicals Cat#S2673; CAS: 
871700-17-3 
Vemurafenib RAF inhibitor Selleck Chemicals Cat#S1267; CAS: 
918504-65-1 
Venetoclax BCL2 inhibitor MedChemExpress CAS: 1257044-40-8 
Cat#HY-15531 
Critical commercial assays 
Caspase-Glo 3/7 Assay Promega Cat#G8091 
AllPrep DNA/RNA/miRNA Universal Kit Qiagen Cat#80224 
HaloPlex Target Enrichment System for Illumina Sequencing Version 
D.3 
Agilent Technologies N/A 
Illumina HiSeq 2500 System Illumina N/A 
Deposited data 
DNA sequencing NCBI Sequence Read 
Archive 
PRJNA531927 
Experimental models: cell lines 
Human: A2058 ATCC Cat#CRL-11147; RRID: 
CVCL_1059 
Human: A375 Laboratory of Richard 
Marais 
RRID: CVCL_5649 
Human: A549 ATCC Cat#CCL-185; 
RRID: CVCL_0023 
Human: AsPC-1 ATCC Cat#CRL-1682; 
RRID: CVCL_0152 
Human: BxPC3 ATCC Cat#CRL-1687 
RRID: CVCL_0186 
Human: Caco-2 ATCC Cat#HTB-37; 
RRID: CVCL_0025 
Human: Calu-6 ATCC Cat#HTB-56; 
RRID: CVCL_0236 
Human: Capan-1 ATCC Cat#HTB-79; 
RRID: CVCL_0237 
Human: CFPAC-1 ATCC Cat#CRL-1918; 
RRID: CVCL_1119 
Human: CHL-1 ATCC Cat#CRL-9446; 
RRID: CVCL_1122 
Human: CO115 Laboratory of Richard 
Hamelin 
RRID: CVCL_D102 
Human: COLO205 ATCC Cat#CCL-222; RRID: 
CVCL_0218 
Human: DLD1 ATCC Cat#CCL-221; 
RRID: CVCL_0248 
Human: HARA JCRB Cat#JCRB1080.0 
RRID: CVCL_2914 
Human: HCA7 ECACC Cat#06061902; 
RRID: CVCL_0289 
Human: HCC15 DSMZ Cat#ACC-496; 
RRID: CVCL_2057 
Human: HCT116 Laboratory of Richard Youle RRID: CVCL_0291 
Human: HCT116 BAK KO Laboratory of Richard Youle N/A 
Human: HCT116 BAX KO Laboratory of Richard Youle N/A 
Human: HCT116 BAK BAX DKO Laboratory of Richard Youle N/A 
Human: HCT8 ECACC Cat#90032006; 
RRID: CVCL_2478 
Human: HMCB ATCC Cat#CRL-9607; 
RRID: CVCL_3317 
Human: HPAC ATCC Cat#CRL-2119; 
RRID: CVCL_3517 
Human: HPAF-II ATCC Cat#CRL-1997; 
RRID: CVCL_0313 
Human: Hs 700T ATCC Cat#HTB-147 
RRID: CVCL_0858 
Human: HT29 ATCC Cat#HTB-38; 
RRID: CVCL_0320 
Human: HuP-T4 ECACC Cat#93121056 
RRID: CVCL_1300 
Human: LoVo Laboratory of Kevin Ryan RRID: CVCL_0399 
Human: LS174T ATCC Cat#CL-188; 
RRID: CVCL_1384 
Human: LS411N ATCC Cat#CRL-2159; 
RRID: CVCL_1385 
Human: MEL-JUSO Laboratory of Judith  
Johnson 
RRID: CVCL_1403 
Human: MeWo ATCC Cat#HTB-65; 
RRID: CVCL_0445 
Human: MIA PaCa-2 ATCC Cat#CRM-CRL-1420; 
RRID: CVCL_0428 
Human: NCI-H520 ATCC Cat#HTB-182; 
RRID: CVCL_1566 
Human: NCI-H727 ATCC Cat#CRL-5815 
RRID: CVCL_1584 
Human: NCI-H747 ATCC Cat#CCL-252; 
RRID: CVCL_1587 
Human: NCI-H838 ATCC Cat#CRL-5844; 
RRID: CVCL_1594 
Human: NCI-H1299 ATCC Cat#CRL-5803; 
RRID: CVCL_0060 
Human: NCI-H1473 ATCC Cat#CRL-5872; 
RRID:CVCL_1472 
Human: NCI-H1793 ATCC Cat#CRL-5896; 
RRID: CVCL_1496 
Human: NCI-H1869 ATCC Cat#CRL-5900; 
RRID: CVCL_1500 
Human: NCI-H2122 ATCC Cat#CRL-5985; 
RRID: CVCL_1531 
Human: NCI-H2286 ATCC Cat#CRL-5938; 
RRID: CVCL_1545 
Human: Panc 02.03 ATCC Cat#CRL-2553; 
RRID: CVCL_1633 
Human: Panc 03.27 ATCC Cat#CRL-2549; 
RRID: CVCL_1635 
Human: Panc 04.03 ATCC Cat#CRL-2555; 
RRID: CVCL_1636 
Human: Panc 08.13 ATCC Cat#CRL-2551; 
RRID: CVCL_1638 
Human: Panc 10.05 ATCC Cat#CRL-2547; 
RRID: CVCL_1639 
Human: PANC-1 ATCC Cat#CRL-1469; 
RRID: CVCL_0480 
Human: PMWK ATCC Cat#CRL-2624; 
RRID: CVCL_A665 
Human: PSN1 ECACC Cat#94060601; 
RRID: CVCL_1644 
Human: RPMI-7951 ATCC Cat#HTB-66; 
RRID: CVCL_1666 
Human: SK-CO-1 ATCC Cat#HTB-39; 
RRID: CVCL_0626 
Human: SK-MEL-2 ATCC Cat#HTB-68D; 
RRID: CVCL_0069 
Human: SK-MEL-5 ATCC Cat#HTB-70; 
RRID: CVCL_0527 
Human: SK-MEL-28 ATCC Cat# HTB-72; 
RRID: CVCL_0526 
Human: SK-MEL-30 DSMZ Cat#ACC-151; 
RRID: CVCL_0039 
Human: SK-MEL-31 ATCC Cat#HTB-73; 
RRID: CVCL_0600 
Human: SW1116 ATCC Cat#CCL-233; 
RRID: CVCL_0544 
Human: SW1417 ATCC Cat#CCL-238; 
RRID: CVCL_1717 
Human: SW48 ATCC Cat#CCL-231; 
RRID: CVCL_1724 
Human: SW480 ATCC Cat#CCL-228; 
RRID: CVCL_0546 
Human: SW620 ATCC Cat#CCL-227; RRID: 
CVCL_0547 
Human: SW837 ECACC Cat#91031104; 
RRID: CVCL_1729 
Human: WM266-4 ESTDAB Cat#ESTDAB-076; 
RRID: CVCL_2765 
Human: WM852 ESTDAB Cat#ESTDAB-084; 
RRID: CVCL_6804 
Human: YAPC DSMZ Cat#ACC-382; 
RRID: CVCL_1794 
Human: PLX4720-resistant A375 (A375 PLX-R) cells AstraZeneca N/A 
Human: Selumetinib-resistant A375 (A375 Sel-R) cells AstraZeneca N/A 
Human: 5 × IC50 PLX4720/selumetinib-resistant A375 (A375 PLX/Sel-
R2) cells 
AstraZeneca N/A 
Human: 10 × IC50 PLX4720/selumetinib-resistant A375 (A375 PLX/Sel-
R1) cells 
AstraZeneca N/A 
Human: MEDI-MEL-07 AstraZeneca N/A 
Human: MEDI-MEL-10 AstraZeneca N/A 
Experimental models: organisms/strains 
Mouse, female: athymic nude mice (CrTac:NCr-Foxn1nu) Taconic Biosciences Cat#TAC:ncrnu; 
RRID:IMSR_TAC:ncrnu  
Mouse, female: NOD SCID (NOD.CB17-Prkdcscid/NCrHsd)  Taconic Biosciences Cat#17002F 
Mouse, female: athymic nude mice (Hsd:Athymic Nude-Foxn1nu) Envigo Cat#069(nu) 
Oligonucleotides 
BCL2L11 (BIM) sequencing primers: 
 
Fwd: 5′- CTAACCCCGGGAAGTCAGAG-3′;  
Rev: 5′- TTGACACATCCTCCATTCCC-3′. 
Sigma-Aldrich N/A 







BCL2L11 (BIM) gRNA #2:  
5′- caccGCAACCACTATCTCAGTGCAA-3′;  
5′- aaacTTGCACTGAGATAGTGGTTGC-3′.  
 
BMF gRNA #1 




pSpCas9(BB)-2A-GFP genome editing vector Feng Zhang, Addgene Cat#48138 
Software and algorithms 
FlowJo FlowJo LLC https://www.flowjo.com/s
olutions/flowjo 
Genedata Screener 12 Genedata https://www.genedata.co
m/products/screener/ 
GraphPad Prism 6 and 7 GraphPad Software https://www.graphpad.co
m/scientific-
software/prism/ 
Ilastik Ilastik Team http://ilastik.org/ 





Study Director Studylog Systems https://www.studylog.co
m/our-products 
VarDict pairwise algorithm AstraZeneca https://github.com/AstraZ
eneca-NGS/VarDict 
BWA-MEM aligner algorithm Heng Li, Broad Institute, 
Cambridge, MA, USA 
https://arxiv.org/abs/1303
.3997 
Seq2C algorithm AstraZeneca https://github.com/AstraZ
eneca-NGS/Seq2C 
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